Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
Richert
Nancy D
ND
D001921:Brain / Q000473:pathology; D018450:Disease Progression; D005500:Follow-Up Studies; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D015203:Reproducibility of Results; D012107:Research Design; D018401:Sample Size; D009626:Terminology as Topic
D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate